NovoCure Limited (NVCR)
NASDAQ: NVCR · Real-Time Price · USD
13.24
-0.25 (-1.85%)
At close: Oct 13, 2025, 4:00 PM EDT
12.98
-0.26 (-1.96%)
Pre-market: Oct 14, 2025, 7:00 AM EDT
NovoCure Revenue
NovoCure had revenue of $158.81M in the quarter ending June 30, 2025, with 5.62% growth. This brings the company's revenue in the last twelve months to $630.16M, up 14.58% year-over-year. In the year 2024, NovoCure had annual revenue of $605.22M with 18.82% growth.
Revenue (ttm)
$630.16M
Revenue Growth
+14.58%
P/S Ratio
2.30
Revenue / Employee
$423,495
Employees
1,488
Market Cap
1.48B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 605.22M | 95.88M | 18.82% |
| Dec 31, 2023 | 509.34M | -28.50M | -5.30% |
| Dec 31, 2022 | 537.84M | 2.81M | 0.53% |
| Dec 31, 2021 | 535.03M | 40.66M | 8.23% |
| Dec 31, 2020 | 494.37M | 143.05M | 40.72% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
NVCR News
- 13 days ago - Novocure to Report Third Quarter 2025 Financial Results - Business Wire
- 14 days ago - Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting - Business Wire
- 4 weeks ago - Novocure's Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC) - Business Wire
- 4 weeks ago - NovoCure Limited (NVCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 6 weeks ago - Novocure Announces Upcoming Investor Events - Business Wire
- 7 weeks ago - Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain - Business Wire
- 7 weeks ago - Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer - Business Wire
- 2 months ago - NovoCure's Wearable Oncology Edge And Compelling Valuation - Seeking Alpha